Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy
Recruiting · NCT06414720 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Udine
View the official record on ClinicalTrials.gov →Interventions studied
Dienogest 2 MG
What this trial is about
This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.
Who can take part
Age range
18 Years to 45 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age \> 18 years
- Fertile age
- Clinical-ultrasound diagnosis or histological diagnosis of endometriosis
- Informed consent
Exclusion criteria
- Pregnancy
- Pre-menarcheal or post-menopausal status
- Chronic pelvic pain syndrome with or without central sensitization assessed with the Central Sensitization Inventory Test (CSI)
- Neoplasia, diabetes, BMI \> 30 kg/m2, coagulopathies, autoimmune diseases, or other conditions that may affect salivary miRNA measurement
- Currently undergoing progestin therapy
Where it is running
1 location listed.
- University of Udine - Udine, UD, Italy